Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease

600 patients aged ≥18 years will be randomised in a 1:1 ratio to nintedanib or placebo. Patients with diagnosis of IPF will be excluded. The study population will be enriched with two-thirds having a usual interstitial pneumonia-like pattern on HRCT. The primary endpoint is the annual rate of declin...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	BMJ open respiratory research 2017-09, Vol.4 (1), p.e000212-e000212
Hauptverfasser:	Flaherty, Kevin R, Brown, Kevin K, Wells, Athol U, Clerisme-Beaty, Emmanuelle, Collard, Harold R, Cottin, Vincent, Devaraj, Anand, Inoue, Yoshikazu, Le Maulf, Florence, Richeldi, Luca, Schmidt, Hendrik, Walsh, Simon, Mezzanotte, William, Schlenker-Herceg, Rozsa
Format:	Artikel
Sprache:	eng
Schlagworte:	Biological products Clinical trials Double-blind studies Evidence-based medicine Interstitial Lung Disease Lung diseases Mortality Patients Pneumonia Population Pulmonary fibrosis Questionnaires
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!